BIOSTAR PHARM-B (02563): Four clinical research achievements of Utidelon were selected for the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

BIOSTAR PHARM-B (02563) announced that four latest clinical research data of the company's core products UTD1 and UTD2 were selected for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The four studies selected for presentation include UTD2 treating late-stage breast cancer I/II clinical trial, UTD2 treating platinum-resistant ovarian cancer II clinical trial, UTD1 treating HER2-positive late-stage breast cancer II clinical trial, and UTD1 treating castration-resistant prostate cancer II clinical trial. Based on the wide spectrum of anti-cancer properties and high oral bioavailability of UTD, Huahao Zhongtian continues to expand into new indications and clinical development of oral formulations. The 2026 ASCO Annual Meeting will be held from May 29th to June 2nd at the McCormick Place Convention Center in Chicago, USA. The annual ASCO meeting brings together clinical oncology experts from around the world to showcase the latest international clinical oncology research findings and cancer treatment technologies.